A Phase II Evaluation of Docetaxel and Carboplatin Followed by Tumor Volume Directed Pelvic Irradiation

PHASE2TerminatedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

April 30, 2005

Primary Completion Date

April 30, 2012

Study Completion Date

June 30, 2012

Conditions

Advanced Endometrial Adenocarcinoma, Stage III A, B, C

Interventions

DRUG

Docetaxel and Carboplatin

docetaxel (75 mg/m2) + carboplatin (AUC 6) IV every 3 weeks X 6 cycles

Trial Locations (2)

Carilion GYN Oncology Associates, Roanoke

Gynecologic Oncology Research & Development, LLC, Greenville